RPT Shielding for Lu-177, Ra-223, and Ac-225

Introduction

RPT shielding is the facility-specific radiation safety review for prepared therapy doses, treated patients, contaminated materials, and radioactive waste. A defensible review estimates external dose and contamination-control needs using the radionuclide, administered activity, source location, time near the source, distance, occupancy, room layout, and waste pathway.

Radiopharmaceutical therapy (RPT) shielding is not one-size-fits-all. Lu-177, Ra-223, and Ac-225 therapies may all fall under the radiopharmaceutical therapy umbrella, but they do not pose the same radiation safety concerns. The radionuclide changes the photon spectrum, the activity handled, the contamination pathway, the waste profile, and the practical shielding question. ^{1, 2}

Unlike CT or fluoroscopy shielding, RPT has no fixed X-ray tube and no predictable beam direction. The source may be a vial, a syringe, a waste container, a treatment chair, a bed, a bathroom, or the patient moving through the facility. That is why a defensible shielding review must be radionuclide- and workflow-specific: it should connect the source term to the actual clinical process, not just copy assumptions from a different therapy isotope.

This guide explains how shielding concerns differ across the three most common RPT radionuclides, what a defensible calculation includes, and how to align the review with NRC, Agreement State, and license requirements. DRPS provides this analysis as part of its radiation shielding design and nuclear medicine physics services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What is RPT shielding?

RPT shielding is the process of evaluating whether facility barriers, localized shielding, waste controls, and work practices keep radiation dose and contamination risk within the facility's design goals, license conditions, and regulatory requirements. It is not limited to treatment-room walls. It includes dose receipt, preparation, administration, patient observation or release, surveys, body-fluid precautions, and radioactive waste storage.

For facilities starting or expanding therapy services, RPT shielding should be reviewed alongside radiation safety officer consulting, radioactive material license support, and PET/CT and nuclear medicine physics support when those services are part of the program.

A practical RPT shielding review starts with a few facility-level questions:

What radionuclide is being used?
What emissions matter for external exposure?
What activity is administered, prepared, or stored?
Where is the source located during receipt, preparation, administration, patient observation, release, and waste storage?
How long are staff, patients, or members of the public near the source?
What rooms or areas are adjacent to the treatment or storage location?
What is the occupancy of those adjacent areas?
What operational controls are already in place?

Those answers will be different for Lu-177, Ra-223, and Ac-225. For background on the emission characteristics that drive these differences, see Understanding Common Isotopes in PET & Radiopharmaceutical Therapy.

How do Lu-177, Ra-223, and Ac-225 shielding concerns compare?

Therapy	Main radiation safety emphasis	Typical shielding concern	Representative photon energies used in practice	Representative gamma-ray dose constant for shielding at 1 m
Lu-177 DOTATATE / Lu-177 PSMA	Photon exposure from patient, dose, and waste	Modest photon shielding review and confirmation	113 keV and 208 keV photons from Lu-177 decay	Approximately 0.007–0.008 µSv·m²/(MBq·h), depending on the dataset and assumptions ^{1, 2}
Ra-223 / Xofigo	Alpha contamination control	Usually not a major structural shielding driver	Low-energy x-rays and gamma emissions from Ra-223 and daughters, including lines in the roughly 80–400 keV range	Approximately 0.02–0.03 µSv·m²/(MBq·h) in ICRP-107-based compilations; verify for the selected dataset ^{1, 2, 6, 7}
Ac-225 therapy	Alpha contamination plus photon contribution from daughters	Localized shielding, waste storage, workflow, and source handling	Prominent emissions from Ac-225 and daughters, including Fr-221 and Bi-213 contributions	Approximately 0.03–0.04 µSv·m²/(MBq·h) for Ac-225 with daughters in equilibrium; verify with current emission data [1,2,8-10]

The numbers in the table are representative starting points, not substitutes for a facility-specific shielding calculation. A defensible calculation should verify the radionuclide data source, geometry, workload, occupancy, broad-beam transmission data, and applicable license or state requirements.

Key Technical Principles

Lu-177: beta therapy with a photon shielding component

Lu-177 therapies such as Lu-177 DOTATATE and Lu-177 PSMA are beta-emitting treatments with low-energy photon emissions. The beta particles deliver therapeutic dose over a short range in tissue and are mostly absorbed locally. For radiation safety outside the patient, the main concern is the photon component, especially the 113 keV and 208 keV photons. ¹

For practical shielding and release calculations, Lu-177 exposure-rate constants should be verified against published radionuclide data such as ICRP Publication 107 and Smith and Stabin's tabulated exposure-rate constants and shielding values. A commonly cited specific gamma-ray constant for Lu-177, when expressed per MBq at 1 m, is on the order of: ^{1, 2}

approximately 0.007–0.008 µSv·m²/(MBq·h)

This number is small, but administered activity is often in the GBq range, so the treated patient can still become the dominant source during and shortly after administration.

Ra-223: contamination control usually dominates

Xofigo, or Ra-223 dichloride, is an alpha-emitting therapy used for metastatic prostate cancer involving bone. Ra-223 and its decay products emit predominantly alpha radiation, with smaller beta and photon components. ⁶

Because the administered activity is relatively low and the photon yield is modest, Ra-223 rarely drives major structural shielding changes in a typical outpatient setting. That does not mean the radiation safety program can be casual.

For Ra-223, the question is usually less:

"How much lead do we need in the wall?"

and more:

"How do we prevent, detect, and manage contamination?"

Ra-223 safety depends heavily on body-fluid precautions, spill response, contamination surveys, and staff training. The photon component should still be understood, but the operational risk is usually dominated by contamination control rather than thick structural barriers. ^{6, 7}

Ac-225: alpha therapy with a photon shielding footprint

Ac-225 is also an alpha-emitting therapy, but it is different from Ra-223. Ac-225 has a decay chain with multiple radioactive daughters, including Fr-221 and Bi-213. While the alpha particles are the main therapeutic emissions, photons from Ac-225 and its daughters can contribute to external dose near sources, waste, and handling areas. [8-10]

For practical radiation protection estimates, published radionuclide data and emission analyses report a specific gamma-ray constant for Ac-225 in equilibrium with its daughters in the approximate range: ^{1, 2, 10}

approximately 0.03–0.04 µSv·m²/(MBq·h)

This value is much higher than a parent-only estimate because daughter emissions contribute significantly to the external photon field. For shielding calculations, it is usually more conservative to evaluate Ac-225 as Ac-225 plus daughters, especially for stored sources, waste, or material that has had time for daughter ingrowth.

That means Ac-225 should not be treated as "just another alpha therapy" from a shielding perspective.

Why RPT shielding differs from imaging-room shielding

In a CT room, the shielding calculation is driven by the X-ray tube, beam direction, workload, scatter, leakage, distance, and occupancy. In RPT, the source is not fixed. It may move through the workflow:

radiopharmacy or dose receipt area
dose preparation area
vial or syringe
treatment chair or bed
patient bathroom
contaminated waste container
decay-in-storage area
treated patient moving through the facility

The radionuclide also changes the problem. Lu-177, Ra-223, and Ac-225 differ in emission type, photon yield, administered activity, patient retention, waste characteristics, and contamination behavior. Copying one radionuclide's SOP or shielding assumption onto another therapy can create gaps: a workflow that is adequate for Lu-177 may underemphasize alpha contamination control for Ra-223 or daughter-product considerations for Ac-225. The same source-movement logic underlies fixed-beam work too — see our PET/CT shielding calculations guide and the general lead shielding design principles for how barrier physics is applied in nuclear medicine.

Clinical Impact

Lu-177 therapy: modest photon shielding, but still needs review

For Lu-177 programs, the shielding review should consider:

activity administered per patient
number of patients treated per week
time spent in the treatment room
distance to adjacent occupied areas
existing wall construction
occupancy of adjacent rooms
waste storage location
use of syringe shields, vial shields, and mobile shielding

In many outpatient Lu-177 programs, existing construction may be adequate, or only modest shielding may be needed, but that should be confirmed by calculation rather than assumed. A full-occupancy office next to a therapy room is very different from a hallway, restroom, storage room, or low-occupancy area.

Ra-223: contamination control is the main operational issue

For Ra-223/Xofigo, the primary concern is contamination control, especially from:

drug handling
blood
urine
feces
vomit
contaminated gloves
absorbent pads
linens
spills or surface contamination

Radiation safety controls should emphasize:

gloves and protective clothing
proper handling of body fluids
spill response procedures
contamination surveys
bathroom and hygiene instructions
waste handling and decay/storage procedures
staff training on alpha contamination risk

The external dose-rate calculation should still be documented, but a low exposure-rate reading does not prove the workflow is safe if alpha contamination controls are weak. For survey and decontamination practices that support this, see choosing the right radiation survey meter and nuclear medicine decontamination best practices.

Ac-225: localized shielding, daughters, waste, and workflow

The Ac-225 program review should include:

activity handled per administration
number of patients treated
whether the dose is prepared onsite or received as a unit dose
time staff spend near the source
location of waste storage
shielding around vials, syringes, and waste containers
workstation layout
survey meter suitability
contamination-control procedures
management of radioactive daughters

Published radiation protection work suggests conservative shielding values for Ac-225 and its daughters may be approximately: ¹⁰

HVL: about 5 mm lead
TVL: about 20 mm lead

These values can be useful for localized shielding around sources and waste, but each facility should evaluate its own workflow, workload, and room layout. For room barriers, broad-beam transmission data are preferred when available because scatter and buildup can affect actual barrier performance.

Practical Optimization Tips

A practical RPT shielding calculation usually follows the same general workflow.

1. Identify the source

The source may be:

prepared dose
patient
waste container
treatment chair
treatment bed
dose preparation area
storage location
bathroom or contaminated waste stream

2. Estimate the workload

Workload depends on:

administered activity
number of patients per week
time in the room
time sources or waste remain in storage
measured or estimated dose rate at 1 meter, using radionuclide-specific gamma constants or measurements

3. Identify control points

For each adjacent area, document:

distance from the source
existing barrier material
occupancy factor
whether the area is controlled or unrestricted
annual or weekly design goal

4. Calculate unshielded dose

Use radionuclide-specific dose-rate constants or measured dose rates, then correct for distance using the inverse square law. Published constants are starting points; facility calculations should use the radionuclide data, calibration assumptions, and source geometry that match the actual clinical workflow. ^{1, 2}

5. Determine required transmission

Compare the unshielded dose to the design goal after applying occupancy. This gives the required barrier transmission.

6. Convert transmission into shielding thickness

For localized shielding, HVL or TVL estimates may be adequate. For room barriers, broad-beam transmission data are preferred when available because scatter and buildup can affect real wall-shielding performance.

Common pitfalls to avoid

Treating all RPT therapies the same. Lu-177, Ra-223, and Ac-225 do not create the same shielding or contamination-control problem.
Assuming alpha therapy means no shielding issue. Ra-223 is usually dominated by contamination control, but Ac-225 daughters can create a meaningful photon component.
Looking only at the treatment room. Waste storage, bathrooms, dose-preparation areas, and patient movement can all matter.
Ignoring occupancy. A wall next to a full-time office is not equivalent to a wall next to a hallway or storage room.
Using structural shielding when operational controls would be more effective. Time, distance, localized shielding, contamination surveys, waste controls, and staff training often reduce dose more effectively than adding unnecessary lead.
Copying one SOP onto another radionuclide. A Lu-177 workflow does not automatically cover Ra-223 or Ac-225 hazards.

Regulatory Considerations

RPT shielding reviews must align with the facility's radioactive material license and the federal or Agreement State rules that govern medical use of byproduct material. The shielding analysis, design goals, and operational controls should be documented so they are defensible during internal review or inspection.

Key frameworks to reference:

10 CFR Part 20 — Standards for Protection Against Radiation, including occupational dose limits and dose limits to members of the public that set the design goals for barriers and operational controls. ³
10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized use, written directives, patient release, and the RSO's responsibilities for therapy radionuclides. ⁴
NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including expectations for facility design, surveys, and radiation safety procedures. ⁵
NRC FSME-13-002 — program-specific guidance for Ra-223 dichloride, relevant to Xofigo programs. ⁷

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada are NRC Agreement States that license medical use under their own radiation-control rules (for example, Florida's program is administered under the state's radiation-control regulations), while Washington, DC is regulated directly by the NRC. A facility must verify which authority issues its license and which dose limits, survey, and reporting requirements apply before relying on any shielding assumption. For Florida-specific context, see Florida Radiation Safety Requirements for Imaging Centers, and for avoiding the most common citations, see Common Radiation Safety Violations and How to Avoid Them.

Facilities starting or expanding therapy services should connect the shielding review to written procedures, waste storage, survey documentation, staff training, and radiation shielding design decisions. If the program is new, expanding, or changing radionuclides, the same review should be coordinated with medical physics consulting, radioactive material license amendments, RSO procedures, and staff training. The review should be consistent with the facility's radioactive material license, 10 CFR Part 20 dose limits, 10 CFR Part 35 medical-use requirements, NRC medical-use licensing guidance, and applicable state radiation-control rules. [3-5]

Frequently Asked Questions (FAQs)

What is RPT shielding?

RPT shielding is the radiation safety evaluation for radiopharmaceutical therapy sources such as prepared doses, treated patients, contaminated materials, and radioactive waste. It estimates external dose and contamination-control needs based on radionuclide emissions, activity, source location, time, distance, occupancy, and workflow.

Does every radiopharmaceutical therapy room need the same shielding?

No. RPT shielding depends on the radionuclide, administered activity, photon emissions, patient retention, source location, waste handling, workload, and adjacent occupancy. A Lu-177 workflow should not be copied directly for Ra-223 or Ac-225 therapy.

How is Lu-177 shielding different from Ra-223 and Ac-225 shielding?

Lu-177 is usually evaluated for modest photon exposure from the patient, dose, and waste. Ra-223 is often dominated by alpha contamination control and body-fluid precautions. Ac-225 requires alpha contamination controls plus attention to photon emissions from radioactive daughters.

Is Ra-223 mainly a structural shielding problem?

Usually no. Ra-223 is an alpha-emitting therapy where contamination control, body-fluid precautions, surveys, and waste handling are usually more important than major structural shielding changes.

Why does Ac-225 need special shielding attention if it is an alpha emitter?

Ac-225 has radioactive daughters that can produce photons contributing to external dose near sources, waste, and handling areas. Shielding reviews should consider Ac-225 and daughter ingrowth, not just the parent alpha emission.

Does Lu-177 therapy usually require new lead-lined walls?

Not automatically. Many outpatient Lu-177 programs may be acceptable with existing construction plus localized shielding and workflow controls, but this should be confirmed with a facility-specific calculation using activity, time, distance, occupancy, room layout, and waste storage assumptions.

When should a facility request an RPT shielding review?

Request a review before starting a new RPT program, adding a new therapy radionuclide, changing treatment rooms, increasing patient volume, moving waste storage, preparing doses onsite, or changing adjacent occupancy near treatment or storage areas.

Key Takeaways

Lu-177 is mainly a photon-shielding issue. The beta particles are mostly absorbed locally, while external exposure is primarily driven by the 113 keV and 208 keV photons.
Ra-223 is usually a contamination-control issue more than a structural-shielding issue. Alpha particles have a short range, but body-fluid and surface contamination pathways still matter.
Ac-225 needs special attention. Its decay chain (including Fr-221 and Bi-213) produces photon emissions that can contribute to dose near sources, waste, and handling locations; evaluate it as Ac-225 plus daughters.
Room shielding depends on workload and occupancy. Adjacent full-occupancy areas require a different review than hallways, restrooms, storage rooms, or low-occupancy areas.
Operational controls still matter. Time, distance, localized shielding, contamination surveys, waste controls, and staff training are often the most effective dose-reduction tools.
Align the review with licensing. Document the analysis against 10 CFR Part 20, 10 CFR Part 35, NUREG-1556 guidance, and the applicable NRC or Agreement State requirements.

Conclusion

RPT shielding is not about adding lead everywhere. It is about understanding the source, controlling the workflow, and applying shielding where it actually reduces dose. Lu-177, Ra-223, and Ac-225 each require a separate review because their physics, contamination pathways, waste handling, and workflow risks differ.

The RSO and medical physicist should avoid treating RPT shielding as a generic checklist item. A defensible review should be radionuclide-specific and workflow-specific, considering emissions, activity, patient retention, source movement, waste handling, room geometry, occupancy, and actual clinical operations. Facilities that treat RPT shielding as a radionuclide-specific process will be better prepared to protect staff, document assumptions, manage waste, and defend the program during internal review or inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps imaging and nuclear medicine facilities translate radiation safety requirements into practical, documented workflows. For radiopharmaceutical therapy programs, this may include radiation shielding design, RPT workflow reviews, waste storage assessments, staff training support, survey documentation reviews, radioactive material license support, and RSO program guidance aligned with NRC and state requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong RPT program is not just about passing an inspection. It is about making the safe process the easy process for the clinical team.

Related DRPS Resources

References

International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). https://www.icrp.org/publication.asp?id=ICRP%20Publication%20107
Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Physics. 2012;102(3):271-291. https://pubmed.ncbi.nlm.nih.gov/22420019/
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. https://www.ecfr.gov/current/title-10/chapter-I/part-20
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. https://www.ecfr.gov/current/title-10/chapter-I/part-35
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. https://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/
U.S. Food and Drug Administration. Xofigo (radium Ra 223 dichloride) prescribing information. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf
U.S. Nuclear Regulatory Commission. FSME-13-002: Program-Specific Guidance About Radium-223 Dichloride. 2013. https://scp.nrc.gov/asletters/program/sp13002.pdf
Laboratoire National Henri Becquerel. Ac-225 decay data tables. http://www.lnhb.fr/nuclides/Ac-225_tables.pdf
PRISMAP. Radionuclide portfolio: Ra-223 and Ac-225. https://www.prismap.eu/radionuclides/portfolio/223Ra/ and https://www.prismap.eu/radionuclides/portfolio/225Ac/
Marengo M, Infantino A. Assessment of emission data and transmission factors supporting radiation protection in the use of 225Ac. Physica Medica. 2022;103:59-65. https://doi.org/10.1016/j.ejmp.2022.10.007